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The epidermal growth-factor receptor (EGFR) tyrosine kinase in-
hibitor erlotinib has been proven to be highly effective in the
treatment of nonsmall cell lung cancer (NSCLC) harboring oncogenic
EGFR mutations. The majority of patients, however, will eventually
develop resistance and succumb to the disease. Recent studies have
identiﬁed secondary mutations in the EGFR (EGFR T790M) and
ampliﬁcation of the N-Methyl-N′-nitro-N-nitroso-guanidine (MNNG)
HOS transforming gene (MET) oncogene as two principal mecha-
nisms of acquired resistance. Although they can account for approx-
imately 50% of acquired resistance cases together, in the remaining
50%, the mechanism remains unknown. In NSCLC-derived cell lines
and early-stage tumors before erlotinib treatment, we have uncov-
ered the existence of a subpopulation of cells that are intrinsically
resistant to erlotinib anddisplay features suggestiveof epithelial-to-
mesenchymal transition (EMT).We showed that activationof TGF-β–
mediated signaling was sufﬁcient to induce these phenotypes. In
particular, we determined that an increased TGF-β–dependent IL-6
secretion unleashed previously addicted lung tumor cells from their
EGFRdependency. Because IL-6 and TGF-β areprominently produced
during inﬂammatory response, we used a mouse model system to
determine whether inﬂammation might impair erlotinib sensitivity.
Indeed, induction of inﬂammation not only stimulated IL-6 secretion
but was sufﬁcient to decrease the tumor response to erlotinib. Our
data, thus, argue thatboth tumor cell-autonomousmechanismsand/
or activation of the tumor microenvironment could contribute to
primary and acquired erlotinib resistance, and as such, treatments
based on EGFR inhibition may not be sufﬁcient for the effective
treatment of lung-cancer patients harboring mutant EGFR.
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In recent years, rapid advances in our understanding of the mo-lecular events required for tumor onset and progression have led
to the development of cancer agents referred to as molecular-
targeted therapies. Because they speciﬁcally target the product of
selective cancer mutations that is required for cancer-cell survival,
they are thought to become invaluable therapeutic tools in the
treatment of cancer. Speciﬁcally in the case of lung cancer, much
excitement has been generated by the ﬁnding that patients harbor-
ing oncogenic epidermal growth-factor receptor (EGFR) muta-
tions highly beneﬁt from treatment with selective inhibitors (i.e.,
erlotinib and geﬁtinib) (1–4). Erlotinib and geﬁtinib are members
of a class of quinazolium-derived agents that inhibit the EGFR
pathway by binding in a reversible fashion to the EGFR ATP
pocket domain (5). Remarkably, retrospective studies showed
a striking correlation between occurrence of certain EGFR on-
cogenic mutations and erlotinib/geﬁtinib responses. The presence
of deletions in exon 19 of EGFR or EGFR L858R missense sub-
stitutions is, in fact, found in more than 80% of nonsmall cell lung
cancer (NSCLC) patients that respond to erlotinib or geﬁtinib
treatment (6). However, as in the case of other targeted therapies,
the emergence of resistance presents a major hurdle for their
successful utilization. Clinical data, in fact, have shown that, in the
majority of the cases, responses to drug treatment are transient
and within a short period, patients that initially responded progress
or relapse with resistant disease. The acquisition of an additional
mutation in exon 20 of EGFR resulting in a threonine-to-methi-
onine substitution at position 790 (T790M mutation) and/or am-
pliﬁcation of c-MET can account for ∼50% of cases of erlotinib-
acquired resistance (7). However, the mechanisms that lead to
resistance in the remaining cases are unknown.
Results
Erlotinib Resistant-Derived Cells Display Mesenchymal-Like Features
and Increased Metastatic Potential. To study molecular mecha-
nisms of geﬁtinib and erlotinib resistance in NSCLC, we have
developed a cell-based system using the broncho-alveolar cancer
cell line H1650. This cell line harbors an oncogenic deletion
within the EGFR (delE746-A750) and has a one-half maximal
inhibitory concentration (IC50) to geﬁtinib or erlotinib treatment
of ∼5 μM. By culturing this cell line in the presence of a constant
high concentration of erlotinib, we have been able to isolate cell
lines capable of growing in the presence of up to 20 μM of the
drug (Fig. 1A). Interestingly, ∼13% of the erlotinib-resistant cells
displayed morphological appearances of mesenchymal cells (i.e.,
16 of a total of 123 colonies examined). These striking morpho-
logical features (Fig. 1B) were associated at the molecular level
with an increased expression of themesenchymal proteinVimentin
and a decreased expression of the epithelial marker E-cadherin
(Fig. 1 C and D). In addition, resistant cells displayed enhanced
motility (Fig. 1E and F) andMatrigel invasion (Fig. 1G) compared
with parental cells.
Erlotinib-Resistant Cells Have a Distinct Gene-Expression Proﬁle and
Are Characterized by an Increased Activation of TGF-β Axis. In
NSCLC, resistance to erlotinib treatment has been associated with
the acquisition of EGFR secondary mutations (EGFR T790M
mutation) and overexpression and/or activation of c-Met (8). None
of these factors were deregulated in any of the selected erlotinib-
resistant cells with mesenchymal-like features that we examined (SI
Appendix, Fig. S1). To identify the molecular mechanisms re-
sponsible for the acquired resistance to erlotinib, we performed
gene-expression proﬁle analysis of the H1650 parental cells and
a resistance-derived cell line. Compared with the parental cells,
H1650-M3 had increased expression of genes previously associated
with epithelial-to-mesenchymal transition (e.g., SNAI, zinc ﬁnger
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E-box binding homeobox (ZEB)2, Vimentin, CD44, TGF-β1, and
TGF-β2), increased motility/invasion (e.g., TGF-β1/2, matrix met-
allopeptidase (MMP)2, and thrombospondin (THBS)1), resistance
to apoptosis (e.g., XAF1) aswell as a lungmetastatic signature (e.g.,
homeobox B (HOXB)2, S100A4, S100A2, and Tenascin C) (SI
Appendix, Fig. S2). Interestingly, many of the differentially expres-
sed genes were previously shown to be regulated by TGF-β. ELISA
also indicated that the increase in TGF-β1 and TGF-β2 mRNA
expression seen in erlotinib-resistant cells correlated with higher
levels of protein secretion (SI Appendix, Fig. S3A). Notably, the
levels of expression and secretion of both TGF-β 1 and 2 did not
change on erlotinib treatment (SI Appendix, Fig. S3B); this was ac-
companied by increased levels of SMAD2 and SMAD3 phosphor-
ylation (SI Appendix, Fig. S3C) as well as an augmented nuclear
translocation of SMAD2 and SMAD4 in the erlotinib-resistant
H1650-M3 cells compared with the H1650 cells (SI Appendix, Fig.
S3D). Based on these ﬁndings, we concluded that the erlotinib-
resistant cells are characterized by an up-regulation of TGF-β–
mediated signaling.
TGF-β1 and TGF-β2 Are Necessary and Sufﬁcient for Erlotinib Resi-
stance, EMT, and Increased Activation of the IL-6 Axis. To determine
the contributions of TGF-β signaling pathways in mediating erlo-
tinib resistance and EMT, we used RNA interference-based tech-
nology to inhibit the expression TGF-β1 and TGF-β2 as well as
SNAI and ZEB2 (two TGF-β axis components previously de-
scribed to be master regulators of EMT). An shRNA-targeting
nexillin (NEXN), a gene expressed at higher levels in the erlotinib-
resistant cells than parental cells but not regulated by TGF-β, was
used as a control. Decreasing the expression of TGF-β1 and TGF-
β2 in the erlotinib-resistant H1650-M3 cells resulted in morpho-
logical changes typical of mesenchymal-to-epithelial transition
(Fig. 2A) as well as decreased cell motility and invasion (SI Ap-
pendix, Fig. S4 A and B). These changes were accompanied at the
molecular level with a decreased expression of Vimentin, SNAI,
and ZEB2 as well as an increased expression of E-cadherin in
TGF-β1 or 2 knockdown erlotinib-resistant cells (Fig. 2 A and B).
Consistent with the role of SNAI in EMT, reducing the expression
of SNAI phenocopied the effect of TGF-β knockdown on levels of
E-cadherin and Vimentin expression as well as on the impairment
of cell motility and invasion (Fig. 2 A and B and SI Appendix, Fig.
S4 A and B). Surprisingly, inhibition of ZEB2 expression caused
only a signiﬁcant increase in E-cadherin mRNA level with no
change in other measured parameters (Fig. 2 A and B and SI
Appendix, Fig. S4 A and B). Interestingly, although neither ZEB2
nor SNAI knockdown modiﬁed the cells sensitivity to erlotinib,
diminishing the expression of TGF-β1 and TGF-β2 resulted in the
restoration of cell erlotinib sensitivity comparable with that of the
parental H1650 cell line (Fig. 2C). Not only were TGF-β1 and 2
required for the observed phenotypes, but we also found that
paracrine stimulation with either TGF-β1, TGF-β2, or both in
combination was sufﬁcient to induce EMT and increase cell mo-
tility and Matrigel invasion (SI Appendix, Fig. S4 C–E) as well as
erlotinib resistance (Fig. 2D). Notably, all these phenotypes re-
quired the constant presence of these factors, because their re-
moval resulted in a reversion from mesenchymal- and erlotinib-
resistant to epithelial- and erlotinib-sensitive. Our data, thus,
clearly indicate that the activation of the TGF-β axis is required
and sufﬁcient for the acquisition of a mesenchymal-like mor-
phology, increased motility and invasion ability, and erlotinib re-
sistance. Because neither ZEB2 nor SNAI knockdown modify the
cells sensitivity to erlotinib, we also concluded that distinct TGF-β
axis components contribute differentially to the erlotinib re-
sistance and the EMT/ invasion program. Therefore, although
a correlation between EMT and erlotinib resistance can be ob-
served, the two programs are clearly distinct and mediated by
different signal transduction pathways.
IL-6 Is Increasingly Expressed in Erlotinib-Resistant Cells and Required
for Their Survival. Among the genes that we found to be in-
creasingly expressed in the erlotinib-resistant cells, we noticed
a dramatic up-regulation of IL-6 and genes reported to be reg-
ulated by IL-6 (SI Appendix, Fig. S2). The increased expression of
IL-6 resulted in an augmented IL-6 secretion (Fig. 3A). IL-6
expression depended on TGF-β–mediated signaling, because
TGF-β1 or TGF-β2 knockdown cells have a reduced expression
of IL-6 and treating cells with either TGF-β1 and/or 2 drastically
increased the expression of IL-6 (Fig. 3 A and B). We were
particularly intrigued by this observation, because Gao et al. (9)
recently showed that NSCLC cells expressing mutant EGFR are
dependent on the IL-6 axis for their long-term proliferation/sur-
vival. We, therefore, hypothesized that an increased autocrine
stimulation of the IL-6/gp130/STAT3 pathway through TGF-β
could unleash the cells from their dependency on EGFR. To this
end, we measured the viability of erlotinib-derived resistant cells
BA
DC
FE
H1650 H1650-M3
H1650
H1650-M3
VI
M
E-
C
ad
H1650 H1650-M3
H1650 H1650-M3
t=
 0
 h
rs
t=
 1
6 
hr
s
G
H1650-M3H1650
40 µl Matrigel
20 µl Matrigel
R
el
at
iv
e 
in
te
ns
ity
0
4
8
12
16
20
0
20
40
60
80
100
120
0 µM 5 µM 10 µM 20 µM
H1650
H1650-M3
H1650-R20
H1650-R25
H1650-R58
%
Erlotinib
 o
f v
ia
bl
e 
ce
lls
H1
65
0
H1
65
0-M
3
H1
65
0-7
3
H1
65
0-R
10
2
Tubulin
E-Cad
VIM
02 06 001-100 -60 -20
-100
-60
-20
100
60
20
Y 
(u
M
)
X (uM)
02 06 001-100 -60 -20
100
60
20
Y 
(u
M
)
-100
-60
-20X (uM)
Fig. 1. Erlotinib-resistant cells are characterized by mesenchymal-like
features and an increased metastatic potential. (A) Parental and resis-
tant cell lines were treated with erlotinib at the indicated concentrations.
Viability of cells was measured after 72 h of treatment by 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The
percentage of viable cells was calculated relative to untreated control. (B)
As shown by scanning electron microscopy, striking morphological differ-
ences were readily observed in certain erlotinib-resistant cells (i.e., 13% of
erlotinib-derived resistant cells). (C) Western blot analysis of cell extracts
with E-cadherin and Vimentin antibodies and (D) immunoﬂuorescence
staining of cells labeled with E-cadherin and Vimentin antibodies. (E )
Images from a time-lapse sequence of erlotinib-sensitive (H1650) and
erlotinib-resistant cells (H1650-M3) migrating to heal a scratch. The images
were taken immediately after scratching the cell monolayer (time = 0 h)
and after 16 h. (F ) Tracking the movement of single cells (n = 12) revealed
differences in intrinsic cell motility. Each trace represents the movement of
a single cell, whereas individual dots designate a frame of 10 min. (G) A
modiﬁed Boyden-chamber assay using ﬁlters coated with different vol-
umes of Matrigel (i.e., 20 μL and 40 μL) showed an increased invasive po-
tential of the erlotinib-resistant cells relative to parental cells. Each dot
represents an individual replicate (n = 5).
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on inhibition of IL-6–mediated signaling. Reduction of the level
of IL-6 by siRNA as well as inhibition of the IL-6 axis by means of
an IL-6 neutralizing antibody or a JAK1/2 inhibitor not only
signiﬁcantly decreased IL-6–mediated signaling (SI Appendix, Fig.
S5A) but also the cell viability (Fig. 3 C and D). Together, these
ﬁndings suggest that although the erlotinib-resistant cells have
become unleashed from their EGFR activity dependence, they
still rely on IL-6–mediated signaling for their survival.
IL-6 Is Sufﬁcient to Modify Sensitivity of Cells to Erlotinib Treatment.
Because both the parental, sensitive cells as well as the resistant
cells express similar levels of IL-6 receptor, we then speculated
that stimulation of cells with IL-6 might decrease sensitivity to
erlotinib treatment in cells expressing mutant EGFR. To explore
this, we measured the effect of IL-6 on the viability of multiple
NSCLC cell lines (HCC827, PC9, and HCC4006) that express
mutant EGFR. Likely as a consequence of the accumulation of
different genetic and epigenetic abnormalities, these cell lines,
despite harboring somatic-activating EGFR mutations, display
different erlotinib sensitivities with IC50s ranging from 5 μM in
the case of H1650 to 0.001 μM in the case of HCC827 (10).
Despite these differences in all cases as shown in Fig. 3E and SI
Appendix, Fig. S5B, the presence of IL-6 in the medium was
sufﬁcient to diminish the sensitivity of various cell lines to erlo-
tinib. Notably, in these experimental settings, IL-6 treatment did
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Fig. 2. The activation of the TGF-β1 and TGF-β2 signaling is required and
sufﬁcient for EMT, increased cell motility and invasion, and erlotinib re-
sistance. (A) To determine the contributions of TGF-β signaling pathways in
mediating erlotinib resistance and EMT, we used RNA interference-based
technology to inhibit the expression of TGF-β1 and TGF-β2 as well as SNAI and
ZEB2. A shRNA-targeting nexillin (NEXN) was used as a control. Two in-
dependent shRNA constructs were used to generate cell lines in which the
expression of each gene of interest was stably knocked down. Although
similar results were obtained with both shRNAs, the ﬁgure depicts the result
obtained with one shRNA only. RT-PCR analysis showed a dramatic decrease
in the expression of the targeted genes. (B) Changes in the expression of
Vimentin and E-cadherin observed by RT-PCR were conﬁrmed by immunos-
taining analysis. (C) Erlotinib-resistant cells in which TGF-β1 and TGF-β2 ex-
pression was silenced displayed sensitivity to erlotinib comparable with that
of the parental cells (H1650). The data shown represent themean value of the
percentage of viable cells ± SD (n = 6; P < 0.0001). (D) Erlotinib-sensitive
(H1650 cells) cells treated for 8 d with TGF-β1, TGF-β2, or TGF-β1 and TGF-β2 in
combination displayed an increased resistance to erlotinib. Cell viability was
measured byMTT assay. The percentage of viable cells was calculated relative
to untreated cells. The bars shown are the means ± SD (n = 4), and the dif-
ferences between the treated and control cells are signiﬁcant (P < 0.0001,
two-tailed Student t test).
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Fig. 3. IL-6 is responsible for the EGFR-independent STAT3 phosphorylation
observed in the erlotinib-resistant cells. (A) TGF-β1 and 2 are required for the
expression of IL-6. The chart represents IL-6 levels in the media secreted by
H1650, H1650-M3 (control) and TGF-β1, or TGF-β2 knockdown cells de-
termined by an ELISA. The data are the means ± SD (n = 4), and the Student t
test showed signiﬁcant difference (t<0.05). (B) TGF-β treatment is sufﬁcient to
induce the expression of IL-6. TheH1650 cells were treated for 2 dwith TGF-β1,
TGF-β2, or both in combination, and the RNA was isolated and subjected to
a quantitative RT-PCR test. The data shown represent the relative expression
level (means± SD; n = 6). (C) Blockage of IL-6 signaling decreased cell viability.
Cells were transfected with the indicated siRNA. After 2 d, the cells viability
was determined byMTT assay and expressed relative to untreated cells (n = 4).
(D) The chart shows the percentage of viable cells relative to control in the
presence of 10 μg/mL IL-6 neutralizing antibody and 2 μM pan-Jak inhibitor
(P6). (Data shown are the means ± SD; P < 0.02). (E) IL-6 is sufﬁcient to modify
sensitivity of cells to erlotinib treatment. Viability of PC9, HCC827, and
HCC4006 cells was determined in the presence of 0.01 mM erlotinib. Of note,
PC9, HCC827, and HCC4006 cells have different basal-cell sensitivities to erlo-
tinib. Cell viability by IL-6 treatment is shown with the means of the percent-
age of viable cells ± SD (n = 6; P ≤ 0.0002). (F) Treatment with the JAK1/2
inhibitor P6 restored the cell sensitivity to erlotinib. Cells were pretreatedwith
IL-6 (10 ng/mL) or IL-6 and P6 (2 μM) and then, treated with erlotinib (5 μM).
After 72 h, cell viability was assessed. Each bar represents the average of four
replicates ± SD (P < 0.01). (G) Schematic representation of our model system.
Paracrine or autocrine stimulation of the TGF-β axis is sufﬁcient to lead to
acquisition of mesenchymal-like morphology, increased motility and invasion
ability, and increased erlotinib resistance. However, in erlotinib-sensitive cells,
mutant EGFR regulates the expression of IL-6; in erlotinib-resistant cells, TGF-β
drives the expression of IL-6 independently of the activation of EGFR and
unleashes the cells from their EGFR activity dependency.
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not substantially affect the cell-proliferation rates but rather,
decreased their apoptotic response. To test whether the effect of
IL-6 was indeed caused by the activation of the gp130-STAT3
axis but not a decreased bioavailability of erlotinib, we measured
the effect of IL-6 treatment on the activation of key components
of the EGFR signaling pathway in cells treated with erlotinib.
Although IL-6 treatment did not have any effect on erlotinib-
mediated inhibition of v-akt murine thymoma viral oncogene
homolog (AKT) activation, it did impair inhibition of STAT3
phosphorylation (SI Appendix, Fig. S5C). Furthermore, treatment
with the P6 JAK1/2 inhibitor restored the cell sensitivity to erloti-
nib, even in the presence of IL-6 (Fig. 3F). In summary, our data
indicate that, independently of the complexity of the genomes of
various NSCLC cell lines, IL-6 activation of the gp130/JAK path-
waywas sufﬁcient to decrease sensitivity to erlotinib. Therefore, we
propose amodel in which paracrine or autocrine stimulation of the
TGF-β axis is sufﬁcient for acquisition of mesenchymal-like mor-
phology, increased motility and invasion ability, and increased
erlotinib resistance. (Fig. 3G).
Erlotinib-Resistant Mesenchymal-Like Cells Are Present in Cell Lines
and Tumors Before Erlotinib Treatment. Gene-expression proﬁle
analysis revealed that CD44 expression was higher and CD24 ex-
pression was lower in the erlotinib-resistant cells compared with
the parental cells (SI Appendix, Fig. S2). Because a subpopulation
of cells that are CD44high/CD24lowmesenchymal highly motile and
invasive has been previously described to exist within both primary
breast carcinomas as well as certain breast cancer-derived cell
lines, we reasoned that erlotinib-resistant mesenchymal-like cells
could exist as a subpopulation within certain lung carcinomas and
as such, could have been present in the parental sensitive H1650
cell line before erlotinib treatment. By FACS analysis, we were
able to conﬁrm the differential expression of CD44 and CD24 in
the erlotinib-resistant compared with parental cells (Fig. 4A) as
well as assess the feasibility of using FACS to separate our putative
target cells from the parental population. Using bivariant plotting
of CD44 and CD24 staining, we were able to identify a sub-
population of cells with features similar to those of the erlotinib-
resistant derived cells within the parentalH1650 population before
drug treatment. Speciﬁcally, we found that in the erlotinib-naïve
H1650 cells, a CD44high/CD24low-enriched cell fraction was char-
acterized by a mesenchymal appearance (Fig. 4B), increased ex-
pression of Vimentin, TGF-β1, TGF-β2, and IL-6, and decreased
levels of E-cadherin (Fig. 4C). Importantly, these cells were also
more resistant to erlotinib treatment compared with the CD44low/
CD24high fraction (Fig. 4D). The presence of CD44high/CD24low
cells was not limited to the H1650 cell line. Populations with
similar properties were also present in several other cell lines. (Fig.
4E). To exclude the possibility that the occurrence of erlotinib-
resistant mesenchymal-like cells was caused by artiﬁcial in vitro
growth conditions and/or events that occurred during establish-
ment of the cell lines, we extended our analysis to cells obtained
from patients with NSCLC. As shown in Fig. 4F and SI Appendix,
Fig. S6 A–C, we were able to identify CD44high/CD24low cells in
preparations from early-stage erlotinib-naïve human NSCLC
tumors as well as the bone marrow of patients with NSCLC. The
CD44high/CD24low cells, like H1650-M3 erlotinib-resistant cells,
had decreased expression of E-cadherin and higher levels of ex-
pression of IL-6, Vimentin, TGF-β1, and TGF-β2 (Fig. 3G). Im-
portantly, to make sure that these cells were bona ﬁde tumor cells,
we also sorted them based on their positivity for the epithelial
marker EpCAM (11) and their lack of expression of the cell-sur-
face markers CD45 and CD31 (SI Appendix, Fig. S6D).
Inﬂammation-Induced IL-6 Expression Decreases the Tumor Sensi-
tivity to Erlotinib.Whereas these data implicate a cell-autonomous
mechanism behind the ontogeny of erlotinib-resistant mesen-
chymal-like cells, the ﬁnding that TGF-β stimulation was sufﬁ-
cient for induction of EMT and decreased sensitivity to drug led
us to hypothesize that the tumor microenvironment may also play
a role in emergent resistance through paracrine signaling. Be-
cause inﬂammation has already been shown to augment expres-
sion levels of IL-6 and TGF-β (12), this concept could provide
intriguing insights into the degree of heterogeneity seen in the
response of NSCLC tumors harboring mutant EGFR to erlotinib
treatment and the occurrence of acquired erlotinib resistance. To
test the hypothesis, we used a mouse-model system previously
described by Vasunia et al. (13) in which cutaneous inﬂammation
and secretion of TGF-β and IL-6 are induced by topical treatment
of the mouse epidermis with low dosage of 12-O-tetradecanoyl-
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Fig. 4. Erlotinib-resistant mesenchymal-like cells are present in cell lines and
tumors before erlotinib treatment. (A) H1650 cells and H1650-M3 cells were
analyzed by ﬂow cytometry for CD44 and CD24 expression. (B) The bright
ﬁeld image of the sorted cells showed that the CD44high/CD24low population
of the H1650 cells has distinct morphology and like H1650-M3 cells, resembles
mesenchymal cells. (C) RT-PCR analysis of sorted cells indicated that cells in the
CD44high/CD24low population of the H1650 cells have increased expression of
Vimentin, TGF-β1, TGF- β2, and IL-6 and diminished expression of E-cadherin
relative to most H1650 cells. (D) Similar to the erlotinib-resistant H1650-M3
cells, the CD44high/CD24low fraction of H1650 cells ismore resistant to erlotinib
treatment than the unsorted H1650 cells. Sorted cells were treated with 5 μM
of erlotinib for 72 h. Cell viability was assessed by MTT assay and expressed
relative to untreated cells (n = 6; P < 0.0001). (E) Flow-cytometry analysis for
CD44 and CD24 of cells harboringmutant EGFR (i.e., HCC827, H1975, PC9, and
HCC4006 cells) and the H1299 cells that are wild-type for the EGFR gene
revealed the presence of subpopulations of cells that are CD44high/CD24low.
The chart represents the percentage of CD44high/CD24low cells relative to total
number of viable cells. (F) NSCLC harbors CD44high/CD24low subpopulations.
Dissociated tumor cells were sorted for CD45, CD31, and EpCAMand analyzed
for CD44 and CD24 expression. (G) Real-time PCR analysis was used to com-
pare CD45−CD31−EpCAM+CD44highCD24low cells with CD45−CD31−Ep-
CAM+CD44lowCD24high cells.
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phorbol-13-acetate (TPA) (13). To provide further evidence that
inﬂammation decreases erlotinib response, we also induced in-
ﬂammation by treatment with LPS. Nu/Nu mice were injected in
the ﬂank with NSCLC cells expressing mutant EGFR. When the
tumors reached a volume of ∼100 mm3, we topically treated the
epidermis with TPA or in the case of LPS, subcutaneous injection
for 5 d. Mice were then treated with erlotinib for 9 d at a dosage
equivalent to the one used in patients (Fig. 5A). Immunostaining
of tumor sections using an anti–IL-6 antibody conﬁrmed that TPA
augmented IL-6 expression in the tumors (Fig. 5 B–D). By com-
paring tumor burden after different treatment conditions, we
found that TPA and LPS treatments dramatically reduced the
response to erlotinib treatment (Fig. 5E and SI Appendix, Fig.
S7A). In accordance with our previous in vitro observations,
immunostaining with Ki67, a commonly used marker of cell
proliferation, and TUNEL assay (to assess apoptosis) showed that
inﬂammation was able to attenuate the effects of erlotinib in vivo,
primarily through the inhibition of apoptosis rather than by in-
crease in cell proliferation (SI Appendix, Fig. S7 B–D). To es-
tablish a causal link between TPA treatment, induction of IL-6,
and diminished erlotinib response, we decreased IL-6 bioavail-
ability by injecting mice with neutralizing antibody speciﬁc to this
cytokine. Cotreatment of mice decreased the effect of TPA and
increased tumor sensitivity to targeted therapy (Fig. 5F).
Discussion
In summary, by selecting cells in high concentration of erloti-
nib, we identiﬁed a subpopulation of erlotinib-resistant cells
with mesenchymal morphology characterized by an EGFR-
independent augmented secretion of TGF-β1 and TGF-β2. We
determined that the increased autocrine secretion of TGF-β was
sufﬁcient to activate a complex program that lead to acquisition of
mesenchymal-like morphology, increased motility and invasion
ability, and increased erlotinib resistance. In the latter case, we
provided evidence that an up-regulation of IL-6 secretion by
TGF-β was sufﬁcient to unleash cells harboring mutant EGFR
from their EGFR dependency, which was manifested by their
decreased sensitivity to erlotinib treatment (Fig. 3A). By using
a surface-marker signature derived from the erlotinib-resistant
cells, we, in addition, showed that cells that are mesenchymal- and
erlotinib-resistant were already present in NSCLC-derived cell
lines as well as in early-stage treatment-naive tumors. These data,
thus, indicate that cell-autonomous mechanisms could generate
subpopulations of cells intrinsically resistant to erlotinib treat-
ment. However, because both IL-6 and TGF-β are secreted fac-
tors prominently produced during the inﬂammatory response, the
activation of the tumor microenvironment could also contribute
to erlotinib resistance. By use of a mouse-model system in which
inﬂammation was induced either by topical treatment with low
concentration of TPA or with LPS, we were indeed able to show
that the induction of inﬂammation was successful in stimulating
IL-6 secretion and decreasing the tumor response to erlotinib
treatment. Thus, our data provide compelling evidence indicating
that acquired resistance to molecular-targeted therapies could
arise not only as a consequence of genetic and/or epigenetic
heterogeneity within cancer cells but also through the activation
of the tumor microenvironment. Because we identiﬁed cells that
are intrinsically resistant to erlotinib in NSCLC before treatment,
it is also tempting to speculate that this same mechanism of
erlotinib-acquired resistance could explain the heterogeneity of
primary erlotinib responses observed in patients. In fact, although
the majority of patients harboring similar EGFR oncogenic
mutations do respond to erlotinib treatment, overall responses
can vary from 5% to 90%, and remission could span 3 mo to more
than 5 y. Notably, several studies have already reported increased
levels of IL-6 in ∼30% of NSCLC (14).
Why IL-6 is required for the survival of the cancer cells is yet
not clear. Our data seems to indicate a role of IL-6 in protecting
cells from apoptosis (SI Appendix, Fig. S5B). This seems to be
consistent with current literature. Catlett-Falcone et al., (15) in
fact, showed that IL-6–induced STAT3 protects myeloma cells
from tumor necrosis factor receptor superfamily, member 6
(FAS)-induced apoptosis by up-regulating the expression of
B-cell CLL/lymphoma 2-like protein X isoformL (BCL-X)L. Sim-
ilarly, Haga et al. (16) show that constitutively active STAT3
provided protection against FAS-mediated liver injury, likely
through an augmented expression of the antiapoptotic proteins
FLICE-like inhibitory protein (FLIP), BCL-2, and BCL-XL. In
agreement with a role of IL-6/STAT3-mediated survival, we ob-
served an up-regulation of Surivin, BCL-X1, and BCL-2 in the
erlotinib-resistant cells.
Interestingly, the erlotinib-resistant cells characterized in this
study also have an increased metastatic potential. They display
mesenchymal-like features, are highly motile and invasive, and
can be found with an increased representation in the bone
marrow of patients compared with primary tumors. Notably,
many of the genes that we see increasingly expressed in the re-
sistant cells compared with the parental line have already been
associated with a metastatic signature and/or with poor prog-
nosis. These genes include HOXB2, S100A4, S100A2, Tenascin
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Fig. 5. Inﬂammation induces IL-6 expression, which decreases the tumor sen-
sitivity toerlotinib. (A) Schematicﬁgureof themousemodel used inour studies.
Mice were injected with H1650 cells s.c. After ∼3 wk, when the tumor reached
a volume of ∼100 mm3, mice were treated topically with TPA or vehicle (ace-
tone) everyotherday.Atday5, themiceweretreatedwitherlotiniborDMSOby
oral gavage for 9 d. At this time, the tumor burden was evaluated. Each time
point represents the average of at least six tumors. (B) TPA treatment induces
expression of IL-6. Formalin-ﬁxed, parafﬁn-embedded sections (4 μm) were
stained for IL-6and counterstainedwithhematoxilin. (C) Proteinexpressionwas
measured by deﬁning regions of interest (ROI) using automated cell acquisition
andquantiﬁcation software for immunohistochemistry (Histoquest). (D) The IL-6
mean intensities in tumors from a representative animal treated with TPA and
a vehicle-treated animal are shown. (E) TPA treatment decreases the tumors
response to erlotinib treatment. The chart represents growth percentage of
tumors. Each column represents the mean volume of eight different tumors. Of
note, similar effects were observed on treatment with LPS (SI Appendix, Fig. S8).
(F) The effects of TPAare, inpart, causedbyan increased secretionof IL-6. Before
erlotinib treatment, mice were injected intraperitoneally with IL-6 neutralizing
antibody (0.08 mg/g) or as a control, with IgG (0.08 mg/g). After 8 d, tumor
burdenwas evaluated, and the averages of four separate tumors were charted.
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C, sushi domain containing (SUSD), melanoma cell adhesion
molecule (MCAM), and transcription factor 4 (TCF-4).
Notably, although EMT has been previously reported to be
associated with erlotinib resistance (17–19), our data indicate that
the programs that lead to mesenchymalization and drug re-
sistance are distinct. Although we found TGF-β to be required
and sufﬁcient for EMT, invasion and motility as well as induction
of an increased expression of IL-6 and reduction of the expression
of the EMT master regulator SNAI only impaired EMT/motility/
invasion but did not change the cells sensitivity to erlotinib. Fur-
thermore, treatment of cells with IL-6 increased their resistance
to erlotinib but did not induce EMT (SI Appendix, Fig. S8). Our
data are consistent with the observation that certain cell lines
harboring mutant EGFR (i.e., PC9), despite being extremely
sensitive to erlotinib, display mesenchymal-like features.
In conclusion, our data provide compelling evidence indicating
that resistance to molecular-targeted therapies could arise not
only as a consequence of genetic and/or epigenetic changes within
cancer cells but also through the activation of the tumor micro-
environment. Thus, the contribution of selective and adaptive
mechanisms adds a layer to the complexity of cancer-drug re-
sistance and poses challenges for the clinical use of molecular-
targeted therapies. In particular, it clearly indicates that, in the
case of lung tumors driven by mutant EGFR, treatment based
only on the inhibition of EGFR will not be effective and suggests
the intriguing possibility that adjunctive therapies designed to
either control inﬂammation and/or decrease the bioavailability of
IL-6 may provide effective means to improve response to EGFR
TKI treatment. Interestingly, clinical trials combining Cox2
inhibitors (e.g., rofecoxib and celecoxib) and geﬁtinib/erlotinib
have already shown encouraging results.
Materials and Methods
Cell Culture. H1650 (H1650), HCC827, H1975 (NCI-H1975), H1299 (NCI-H1299),
and HCC4006 were obtained from the American Type Culture Collection re-
pository. The PC9 cell line was a gift from Jeff Engelman (MGH, Charlestown,
MA). All of the cell lines were cultured in Roswell Park Memorial Institute
medium supplemented with 5% FBS, glutamine, penicillin, and streptomycin.
The lentiviral packaging cell line HEK293T was cultured in DMEM containing
10% FBS, penicillin, streptomycin, and sodium pyruvate.
Antibodies and Reagents. The following antibodies were used in this study:
mouse anti–E-cadherin antibody (BD Transduction Laboratories), monoclonal
anti-Vimentin antibody (RV202; Santa Cruz Biotechnology), mouse anti–β-
Tubulin antibody (2-28-33; Santa Cruz Biotechnology), mouse anti-STAT3 an-
tibody (124H6; Cell Signaling Technology), and rabbit anti–phospho-STAT3
antibody (D3A7; Cell Signaling Technology). The Smad molecules were
detected with the Phospho-Smad antibody Sampler Kit from Cell Signaling
Technology. Erlotinib hydrochloride was purchased from LGM Pharmaceut-
icals, Inc. Recombinant IL-6 (rhIL6), anti–IL-6 monoclonal antibody (MAB206),
and anti–IL-6R antibody (AB-227-NA) were obtained from R&D Systems.
Recombinant TGFβ1/2 was purchased from Sigma-Aldrich. Human recombi-
nant EGF was purchased from Millipore. The JAK 1/2 inhibitor tetracyclic pyr-
idone 2-tert-butyl-9-ﬂuoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-
7-one, pyridone 6 (P6) was purchased from Calbiochem.
SI Appendix has further descriptions of the experimental procedures de-
scribed in this paper. Human tissues were obtained from CT Surgery De-
partment, Weill Cornell Medical College, and patient consent was obtained
according to approved IRB protocols from the institution.
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